Clinical Trials Browser

Phase 2 × Neoplasms, Plasma Cell × Stem Cell Transplantation × Clear all

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00303719 2020-05-12

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Phase 2 Terminated

342 enrolled 14 charts

GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Kidney Neoplasms, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2 Completed

75 enrolled 11 charts

Plasma cell

Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00968396 2013-04-05

Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Clinical Trials

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts